Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab + carfilzomib + pomalidomide + dexamethasone in newly diagnosed multiple myeloma with renal failure
2020-003092-18Phase 2Active
- Sponsor
- Medical University of Innsbruck
- Start
- Mar 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of daratumumab, carfilzomib, pomalidomide and dexamethasone in multiple myeloma (MM) (2 cohorts), sponsored by Medical University of Innsbruck. Primary endpoint: Feasibility. Started Mar 2021; status: active.
02
Drugs
daratumumabcarfilzomibpomalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2020-003092-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003092-18.